Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pancreatic kininogenase plus CSII for newly diagnosed type 2 diabetes
ChiCTR1800015918Phase 4Not yet recruiting
- Sponsor
- Nanjing First Hospital
- Start
- May 2018
- Modality
- Recombinant Proteins and Enzymes, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pancreatic kininogenase and human insulin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Nanjing First Hospital. Primary endpoints: Mean blood glucose, Mean amplitude of glycemic excursions and 2 more. Planned start May 2018; status: not yet recruiting.
02
Drugs
pancreatic kininogenasehuman insulin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1800015918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015918.